AnHeart

AnHeart is owned by Nuvation Bio.

Nuvation Bio is one of the...

• Russell 3000.

Nuvation Bio is a company listed under the stock ticker NUVB (US).

Acquisition, funding and merger involving Nuvation Bio.

• Nuvation Bio has announced the acquisition of AnHeart  (posted on April 12 2024).

View the org chart displaying its 15 main executives

Most searched biographies at AnHeart

• Junyuan Wang, Co-Founder and Chief Executive Officer
• Wei Xu, Director
• Xiaohang Tong, Director

Popular executive movements at AnHeart

• Amy Muse has joined the company as Vice President, US Commercial  (posted on November 10 2023).
• Guilin Huang has joined the company as Senior Vice President, Development  (posted on November 10 2023).
• Charlotte Arnold has joined the company as Chief Corporate Affairs Officer  (posted on September 29 2023).

Popular executive movements at Nuvation Bio

• Colleen Sjogren has joined the company as Chief Commercial Officer  (posted on March 29 2024).
• Robert Mashal has joined the company as Director  (posted on January 9 2024).
• Jennifer Fox, Chief Financial Officer, has left the company  (posted on November 14 2023).

Create your alert
to follow the executive moves at AnHeart.

Nuvation Bio has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by AnHeart

• Nuvation Bio Completes Acquisition of AnHeart Therapeutics
• Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
• AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
• AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
• AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
• AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
• AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads
• AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
• AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
• AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer
• View more press releases Close

Social media about AnHeart

• AnHeart on Wikipedia, Google News & Yahoo Finance
• AnHeart on LinkedIn, Twitter & YouTube

Contact by email its executives including Junyuan Wang

Call AnHeart at +1 212...

View the org chart

Register to receive your alert

Report an error